[
    {
        "file_name": "ArtaraTherapeuticsInc_20200110_8-K_EX-10.5_11943350_EX-10.5_LicenseAgreement.txt",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.2 Approval Milestone based on Data Value: Within forty-five (45) days of an approval of the TARA-002 BLA by the FDA, ArTara will pay a one- time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002's BLA filing, as set forth below:\n\nOfficial Feedback from FDA regarding the Program Data Milestone\n[…***…] $[…***…]\n[…***…] $[…***…]\n[…***…] $[…***…]\n[…***…] $[…***…]",
                "changed_text": "3.2 Approval Milestone based on Data Value: Within thirty (30) days of an approval of the TARA-002 BLA by the FDA, ArTara will pay a one- time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002's BLA filing, as set forth below:\n\nOfficial Feedback from FDA regarding the Program Data Milestone\n[…***…] $[…***…]\n[…***…] $[…***…]\n[…***…] $[…***…]\n[…***…] $[…***…]",
                "explanation": "This change introduces a contradiction in payment terms. Originally, ArTara has 45 days to pay the approval milestone. The modification reduces this timeframe to 30 days, creating a direct conflict and uncertainty regarding the actual payment deadline.",
                "location": "Section 3.2"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.3 Royalties. Royalties will be payable by ArTara on Net Sales of Product in the Indication. ArTara will, no later than […***…] following the close of each calendar quarter, pay tiered Royalties based on annual Net Sales of Product in the Indication as set forth below:\n\nAnnual Net Sales of Product for the Indication Annual Royalty Rate Percent Net Sales\n\n$0 - $25,000,000 1.75%\n\n>$25,000,000 - $50,000,000 2.25%\n\n>$50,000,000 2.50%",
                "changed_text": "3.3 Royalties. Royalties will be payable by ArTara on Net Sales of Product in the Indication. ArTara will, no later than […***…] following the close of each calendar quarter, pay tiered Royalties based on annual Net Sales of Product in the Indication as set forth below:\n\nAnnual Net Sales of Product for the Indication Annual Royalty Rate Percent Net Sales\n\n$0 - $25,000,000 1.75%\n\n>$25,000,000 - $50,000,000 2.25%\n\n>$50,000,000 2.00%",
                "explanation": "This change creates a contradiction in the Royalty rates. The original text specifies 2.50% for Net Sales > $50,000,000. The change modifies it to 2.00%, creating an inconsistency in the royalty payment structure depending on which section of the contract is followed, thus creating a payment term conflict.",
                "location": "Section 3.3"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "7.1 ArTara, Affiliates, and sublicensees will obtain and maintain commercial general liability insurance with a reputable and financially secure insurance carrier prior to clinical testing, making, using, importing, offering to sell, or selling any licensed Product or engaging in any other act involving any licensed Product or the patent rights, if such act could possibly create risk of a claim against University Indemnitees for personal injury or property damage.\n(a) The insurance will identify University Indemnitees as additional insureds and will provide that the carrier will notify University in writing at least […***…] prior to cancellation, non-renewal, or material change in coverage. Should ArTara fail to obtain replacement insurance providing comparable coverage within such […***…] period, University will have the right to termination this Agreement effective as of the end of the […***…] period without notice or any additional cure period.",
                "changed_text": "7.1 ArTara, Affiliates, and sublicensees will obtain and maintain commercial general liability insurance with a reputable and financially secure insurance carrier prior to clinical testing, making, using, importing, offering to sell, or selling any licensed Product or engaging in any other act involving any licensed Product or the patent rights, if such act could possibly create risk of a claim against University Indemnitees for personal injury or property damage.\n(a) The insurance will identify University Indemnitees as additional insureds and will provide that the carrier will notify University in writing at least […***…] prior to cancellation, non-renewal, or material change in coverage. Should ArTara fail to obtain replacement insurance providing comparable coverage within such […***…] period, University will have the right to termination this Agreement effective immediately without notice or any additional cure period.",
                "explanation": "This creates a direct conflict regarding termination rights if insurance requirements aren't met. The original allows for a cure period. The modification removes the cure period, allowing immediate termination, introducing a contradictory enforcement of the insurance clause.",
                "location": "Section 7.1"
            }
        ]
    }
]